Clinical trial
Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500…
NCT00415636 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00415636 |
|---|---|
| Title | Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer |
| Official title | A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | IC83/LY2603618, pemetrexed |
| Enrollment | 31 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Dec 25, 2006 |
| Last update posted | Oct 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: